Metformin and the gastrointestinal tract
Open Access
- 16 January 2016
- journal article
- review article
- Published by Springer Science and Business Media LLC in Diabetologia
- Vol. 59 (3), 426-435
- https://doi.org/10.1007/s00125-015-3844-9
Abstract
Metformin is an effective agent with a good safety profile that is widely used as a first-line treatment for type 2 diabetes, yet its mechanisms of action and variability in terms of efficacy and side effects remain poorly understood. Although the liver is recognised as a major site of metformin pharmacodynamics, recent evidence also implicates the gut as an important site of action. Metformin has a number of actions within the gut. It increases intestinal glucose uptake and lactate production, increases GLP-1 concentrations and the bile acid pool within the intestine, and alters the microbiome. A novel delayed-release preparation of metformin has recently been shown to improve glycaemic control to a similar extent to immediate-release metformin, but with less systemic exposure. We believe that metformin response and tolerance is intrinsically linked with the gut. This review examines the passage of metformin through the gut, and how this can affect the efficacy of metformin treatment in the individual, and contribute to the side effects associated with metformin intolerance.Keywords
This publication has 88 references indexed in Scilit:
- Human Gut Microbiota Changes Reveal the Progression of Glucose IntolerancePLOS ONE, 2013
- Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesityProceedings of the National Academy of Sciences of the United States of America, 2013
- Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of actionCore Evidence, 2012
- Na+-d-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin SecretionDiabetes, 2011
- GLUT2 Accumulation in Enterocyte Apical and Intracellular MembranesDiabetes, 2011
- Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease BiomarkerPLOS ONE, 2010
- TGR5-Mediated Bile Acid Sensing Controls Glucose HomeostasisCell Metabolism, 2009
- Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS StudyDiabetes, 2009
- Metformin Transport by a Newly Cloned Proton-Stimulated Organic Cation Transporter (Plasma Membrane Monoamine Transporter) Expressed in Human IntestineDrug Metabolism and Disposition, 2007
- Clinical Pharmacokinetics of MetforminClinical Pharmacokinetics, 1996